Evaluation of preoperative serum markers for individual patient prognosis in stage I-III rectal cancer

Tumor Biology

Volumn 35, Issue 10, 2014, Pages 10237-10248

  Giessen, Clemens ^a   Nagel, Dorothea ^a   Glas, Maria ^a   Spelsberg, Fritz ^a   Lau Werner, Ulla ^a   Modest, Dominik Paul ^a   Michl, Marlies ^a   Heinemann, Volker ^a   Stieber, Petra ^a   Schulz, Christoph ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Acute phase proteins; CEA; Colorectal cancer; Prognostic factors; SAA; Tumormarker

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; SERUM AMYLOID A; TUMOR MARKER;

ADULT; AGED; AREA UNDER THE CURVE; BLOOD; CANCER STAGING; DISEASE FREE SURVIVAL; FEMALE; HUMAN; IMMUNOASSAY; KAPLAN MEIER METHOD; LUMINESCENCE; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PREOPERATIVE PERIOD; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; RECTUM TUMOR; RETROSPECTIVE STUDY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; CARCINOEMBRYONIC ANTIGEN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOASSAY; KAPLAN-MEIER ESTIMATE; LUMINESCENT MEASUREMENTS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREOPERATIVE PERIOD; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECTAL NEOPLASMS; RETROSPECTIVE STUDIES; ROC CURVE; SERUM AMYLOID A PROTEIN; TUMOR MARKERS, BIOLOGICAL;

EID: 84922395361     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-2338-6     Document Type: Article

References (31)

1. Ferlay J et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374-403.
2. Duffy MJ et al. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer. 2007;43(9):1348-60.
3. Locker GY et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006;24(33):5313-27.
4. Yamashita K, Watanabe M. Clinical significance of tumor markers and an emerging perspective on colorectal cancer. Cancer Sci. 2009;100(2):195-9.
5. Van Cutsem E et al. Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Ann Oncol. 2010;21 suppl 5:v93-7.
6. Locker GY et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006;24(33):5313-27.
7. Behbehani AI et al. Prognostic significance of CEA and CA 19-9 in colorectal cancer in Kuwait. Int J Biol Markers. 2000;15(1):51-5.
8. Reiter W et al. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer. Anticancer Res. 2000;20(6D):5195-8.
9. Hofmann, D., et al., Prognosis in non-metastatic colorectal cancer: multivariate evaluation of preoperative levels of six tumor markers in addition to clinical parameters, in LaboratoriumsMedizin 2007. p. 76.
10. Louhimo J et al. Serum HCG beta, CA 72-4 and CEA are independent prognostic factors in colorectal cancer. Int J Cancer. 2002;101(6):545-8.
11. Webb A et al. The prognostic value of CEA, beta HCG, AFP, CA125, CA19-9 and C-erb B-2, beta HCG immunohistochemistry in advanced colorectal cancer. Ann Oncol. 1995;6(6):581-7.
12. Holdenrieder S et al. Cytokeratin serum biomarkers in patients with colorectal cancer. Anticancer Res. 2012;32(5):1971-6.
13. Biran H et al. Serum amyloid A (SAA) variations in patients with cancer: correlation with disease activity, stage, primary site, and prognosis. J Clin Pathol. 1986;39(7):794-7.
14. Bystrom P et al. Evaluation of predictive markers for patients with advanced colorectal cancer. Acta Oncol. 2012;51(7):849-59.
15. Glojnaric I et al. Serum amyloid A protein (SAA) in colorectal carcinoma. Clin Chem Lab Med. 2001;39(2):129-33.
16. Hansen, M.T., et al., A link between inflammation and metastasis: serum amyloid A1 and A3 induce metastasis, and are targets of metastasis-inducing S100A4. Oncogene, 2014.
17. McShane LM et al. REporting recommendations for tumour MARKer prognostic studies (REMARK). Eur J Cancer. 2005;41(12):1690-6.
18. Modest DP et al. Outcome of patients with metastatic colorectal cancer depends on the primary tumor site (midgut vs. hindgut): analysis of the FIRE1-trial (FuFIRI or mIROX as first-line treatment). Anti-Cancer Drugs. 2014;25(2):212-8.
19. Schmoll HJ et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol. 2012;23(10): 2479-516.
20. Harrell Jr FE et al. Regression modelling strategies for improved prognostic prediction. Stat Med. 1984;3(2):143-52.
21. Park YJ et al. Prognostic factors in 2230 Korean colorectal cancer patients: analysis of consecutively operated cases. World J Surg. 1999;23(7):721-6.
22. Park YJ et al. Experience of 1446 rectal cancer patients in Korea and analysis of prognostic factors. Int J Color Dis. 1999;14(2):101-6.
23. Malle E, Sodin-Semrl S, Kovacevic A. Serum amyloid A: an acutephase protein involved in tumour pathogenesis. Cell Mol Life Sci. 2009;66(1):9-26.
24. Shiels, M.S., et al., Circulating inflammation markers and prospective risk of lung cancer. J Natl Cancer Inst, 2013;105(24):1871-80.
25. Toriola AT et al. Biomarkers of inflammation are associated with colorectal cancer risk in women but are not suitable as early detection markers. Int J Cancer. 2013;132(11):2648-58.
26. Stotz M et al. The preoperative lymphocyte to monocyte ratio predicts clinical outcome in patients with stage III colon cancer. Br J Cancer. 2014;110(2):435-40.
27. Spencer SK et al. Prognostic/predictive value of 207 serum factors in colorectal cancer treated with cediranib and/or chemotherapy. Br J Cancer. 2013;109(11):2765-73.
28. Mehrkhani F et al. Prognostic factors in survival of colorectal cancer patients after surgery. Color Dis. 2009;11(2):157-61.
29. Stocchi L et al. Impact of surgical and pathologic variables in rectal cancer: a United States community and cooperative group report. J Clin Oncol. 2001;19(18):3895-902.
30. Ng K et al. Circulating 25-hydroxyvitamin d levels and survival in patients with colorectal cancer. J Clin Oncol. 2008;26(18):2984-91.
31. Zgaga, L., et al., Plasma vitamin D concentration influences survival outcome after a diagnosis of colorectal cancer. Journal of Clinical Oncology, 2014.Jul 7. pii: JCO.2013.54.5947. [Epub ahead of print]